We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Responsible for Contact Inhibition Lacking in Skin Cancer Cells

By LabMedica International staff writers
Posted on 08 Jun 2011
Loss of the tumor suppressing protein alpha-E (alpha-epithelial) catenin triggers a complex series of molecular events that ultimately result in the development of skin squamous-cell carcinoma.

The adhesion protein alpha-E catenin has been implicated in limiting epithelial cell proliferation under conditions of high cell density (a process called contact inhibition of cell proliferation). More...
To better study the role of this protein, investigators at Fred Hutchinson Cancer Research Center (Seattle, WA, USA) genetically engineered a line of mice that lacked the gene for alpha-E catenin in their hair follicle stem cells.

They reported in the May 24, 2011, issue of the journal Science Signaling that these animals developed squamous cell carcinomas, thus providing genetic evidence that alpha-E-catenin was a tumor suppressor. The investigators identified the transcriptional coactivator Yap1 as a protein that interacted with alpha-E-catenin. This interaction inhibited the activity of Yap1 and prevented Yap1 from translocating to the nucleus. Yap1 was also a target for the Hippo signaling pathway, which restricts cell proliferation and organ size by blocking the nuclear translocation of Yap1.

In human squamous cell carcinoma tumors, alpha-E-catenin abundance was inversely correlated with Yap1 activation. Thus, alpha-E-catenin may exert its tumor-suppressive effects by sequestering Yap1 and thereby limiting its activity.

"The fact that alpha-catenin-deficient mice developed skin cancer led us to conclude that the loss of this protein is an important event in cancer development, and that alpha-catenin functions as a tumor suppressor," said senior author Dr. Valeri Vasioukhin, associate professor human biology at Fred Hutchinson Cancer Research Center. "We also found that unlike normal cells, alpha-catenin-mutant cells cannot stop dividing when they become very crowded in the Petri dish – this characteristic is one of the hallmarks of cancer cells."

"We found that alpha-catenin controls cell proliferation by regulating Yap1, which is active in cells missing alpha-catenin. Therefore, Yap1 is likely to be an excellent target for the treatment of patients with squamous cell carcinoma," said Dr. Vasioukhin.

Related Links:

Fred Hutchinson Cancer Research Center





Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.